John Salsman to Antineoplastic Agents
This is a "connection" page, showing publications John Salsman has written about Antineoplastic Agents.
Connection Strength
0.537
-
Salsman JM, Grunberg SM, Beaumont JL, Rogers M, Paul D, Clayman ML, Cella D. Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Canc Netw. 2012 Feb; 10(2):149-57.
Score: 0.276
-
Roth ME, Parsons SK, Ganz PA, Wagner LI, Hinds PS, Alexander S, Bingen K, Bober SL, Brackett J, Cella D, Henry NL, Indelicato DJ, Johnson RH, Miller TP, Rosenberg SM, Schmitz KH, Thanarajasingam G, Reeve BB, Salsman JM. Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials. J Natl Cancer Inst. 2023 Jan 10; 115(1):21-28.
Score: 0.147
-
Salsman JM, Yanez B, Smith KN, Beaumont JL, Snyder MA, Barnes K, Clayman ML. Documentation of Fertility Preservation Discussions for Young Adults With Cancer: Examining Compliance With Treatment Guidelines. J Natl Compr Canc Netw. 2016 03; 14(3):301-9.
Score: 0.092
-
Beaumont JL, Salsman JM, Diaz J, Deen KC, McCann L, Powles T, Hackshaw MD, Motzer RJ, Cella D. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Cancer. 2016 Apr 01; 122(7):1108-15.
Score: 0.023